Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.
Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. Kavanaugh A, et al. Among authors: purcaru o. Ann Rheum Dis. 2015 Jan;74(1):44-51. doi: 10.1136/annrheumdis-2014-205198. Epub 2014 Jun 18. Ann Rheum Dis. 2015. PMID: 24942382 Free PMC article. Clinical Trial.
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Emery P, et al. Among authors: purcaru o. Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10. Ann Rheum Dis. 2017. PMID: 27165179 Free PMC article. Clinical Trial.
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, Koetse W, Purcaru O, Bennett B, Burkhardt H. Smolen JS, et al. Among authors: purcaru o. Ann Rheum Dis. 2015 May;74(5):843-50. doi: 10.1136/annrheumdis-2013-204632. Epub 2014 Jan 15. Ann Rheum Dis. 2015. PMID: 24431394 Free PMC article. Clinical Trial.
Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P. Hazes JM, et al. Among authors: purcaru o. Rheumatology (Oxford). 2010 Oct;49(10):1900-10. doi: 10.1093/rheumatology/keq109. Epub 2010 Jun 14. Rheumatology (Oxford). 2010. PMID: 20547658 Free PMC article.
Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis.
van dH, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A. van dH, et al. Among authors: purcaru o. Value Health. 2014 Nov;17(7):A387. doi: 10.1016/j.jval.2014.08.2653. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200883 Free article. No abstract available.
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.
Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, Heijde Dv, Vollenhoven Rv, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Emery P, et al. Among authors: purcaru o. Ann Rheum Dis. 2016 Oct;75(10):e69. doi: 10.1136/annrheumdis-2016-210083. Epub 2016 Aug 12. Ann Rheum Dis. 2016. PMID: 27519773 Free article. No abstract available.
24 results